Our technology
Baxiva’s platform enables the rapid development of vaccines targeting the serotype-specific polysaccharides of Gram-negative bacteria. Our proprietary chemical conjugation strategy links the bacterial polysaccharides to virus-like particles (VLPs), producing highly immunogenic glycoconjugates. This approach streamlines the development of highly multivalent vaccines targeting both known and emerging bacterial pathogens—offering a powerful tool in the fight against drug-resistant infections.
Contact us
Interested in learning more? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Wagistrasse 18
8952 Schlieren
Switzerland